Compound blood pressure reducing prepn containing angiotonin converzyme inhibitor, calcium ion agonist and Estazolam

A technology of converting enzyme inhibitors and calcium ion antagonists, applied in the field of compound antihypertensive preparations, can solve problems such as unsatisfactory and side effects reduction

Inactive Publication Date: 2004-09-08
杜晓锋
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the side effects of the compound preparation have been reduced, it is still unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-7

[0053] Preparation of compound antihypertensive preparation

[0054] The enalapril used is enalapril maleate tablets, produced by Yangzijiang Pharmaceutical; Production. The calcium ion antagonist nifedipine is nifedipine, produced by Changzhou Pharmaceutical Factory; amlodipine is Norvasc, produced by Pfizer Pharmaceuticals; and nitrendipine is produced by Nantong No. 3 Pharmaceutical Factory. Estazolam is produced by Beijing Yimin Pharmaceutical.

[0055] The formulations in Table 1 are prepared into capsules according to the conventional method in the pharmaceutical industry, and there are 21 kinds in total.

[0056] Example

Embodiment 8

[0058] Combined administration of angiotensin-converting enzyme inhibitors, calcium antagonists and estazolam

[0059] The present invention uses prospective, control group, single-blind, multi-center clinical trials to randomly divide 160 hypertensive patients into Nazepril group, Nifedipine group, Enalapril combined with Nifedipine compound preparation group, and Napril combined with nifedipine and estazolam compound preparation group was observed and treated for an average of 6 months.

[0060] Table 2 enalapril group, nifedipine group, enalapril combined with nifedipine compound preparation group, and

[0061] group

average dose

mg

Mean blood pressure mmHg

treatment result

Before treatment

After treatment

Average Buck

Amplitude%

Compliance rate

%

Efficient

%

1 enalapril

Group n = 39

15.4±8.2

159.7±17.7 /

91.1±7.6

141.2±16.8 /

84.6±6.8

11.6...

Embodiment 9

[0084] Combined administration of angiotensin-converting enzyme inhibitors, calcium antagonists and estazolam

[0085] In the present invention, prospectively, with a control group, single-blind, 122 patients with essential hypertension were randomly divided into ramipril group, amlodipine group, ramipril combined with amlodipine compound preparation group, and ramipril group. The Puli combined with amlodipine and estazolam compound preparation group was observed and treated for an average of 8 weeks.

[0086] Table 4 ramipril group, amlodipine group, ramipril combined with amlodipine compound preparation group, and

[0087] group

average dose

mg

Mean blood pressure mmHg

treatment result

Before treatment

After treatment

Average Buck

Amplitude%

Compliance rate

%

Efficient

%

1 ramipril

Group n = 30

10.8±7.4

157.8±16.9 / 9

0.5±6.8

140.7±15.7

/

85.1±5.9

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides one new kind of compound blood pressure reducing preparation containing angiotonin converzyme inhibitor, calcium ion agonist, Estazolam and pharmaceutically acceptable carrier. The angiotonin converzyme inhibitor is selected from Enalapril, Ramipril, Benalapril, Lisinopril, Acertil, etc. as well as their mixture; and the calcium ion agonist is selected from Nitrendpine, Amlodipine Besylate, Nifedipine, Felodipine, etc. as well as their mixture. The present invention utilizes the synergistic effect between different medicines to raise the blood pressure lowering effect, reduce side effect and improve the compliance of patient.

Description

technical field [0001] The invention relates to a novel compound antihypertensive preparation, in particular to a compound antihypertensive preparation containing an angiotensin-converting enzyme inhibitor, a calcium ion antagonist and estazolam. Background technique [0002] In recent years, most large-scale international authoritative hypertension clinical trials and hypertension treatment guidelines based on evidence-based medicine have shown that increasing the pressure reduction can actively and durably reduce the blood pressure of hypertensive patients to below 130 / 85 mm Hg ( It should be lowered to below 120 / 80 mm Hg), which can effectively reduce the damage of target organs such as heart, brain and kidney caused by high blood pressure, reduce or delay stroke, coronary heart disease, angina pectoris, myocardial infarction, renal failure, atherosclerosis, etc. It can reduce the occurrence of complications such as sclerosis and aneurysm, reduce the rate of cardiovascula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K9/22A61K9/48A61K9/52A61K31/5517A61K45/00A61P9/12
Inventor 徐南图
Owner 杜晓锋
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap